Erdafitinib Wins Traditional Approval for FGFR3-Altered Urothelial Cancer

This FDA approval summary details the pivotal THOR Cohort 1 overall survival benefit and refined labeling that oncology and supportive care pharmacists must understand for second-line FGFR3-altered urothelial carcinoma management.

📅 Journal publication: Aug 12, 2026 · Last updated: Oct 7, 2026

erdafitinibFGFR3FGFR inhibitorurothelial carcinomabladder cancerTHORBLC3001FDA approvaltargeted therapyoverall survivalcompanion diagnosticpembrolizumab Oncology Pharmacy

Background Information

Erdafitinib boosts survival in advanced FGFR3-altered bladder cancer.

Erdafitinib offers an effective treatment option for patients with advanced urothelial carcinoma who have specific FGFR3 genetic alterations. The study demonstrated a statistically significant improvement in overall survival with erdafitinib: median OS was 12.1 months compared to 7.8 months with chemotherapy. Erdafitinib is approved for patients with FGFR3-altered urothelial carcinoma after prior systemic therapy, but not for those eligible for PD-(L)1 inhibitors. Erdafitinib improves survival in FGFR3-altered advanced urothelial carcinoma post-chemotherapy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Maguire WF, Chang E, Mulkey F, Hsu V, Wu H, Truong TM, Kappel D, Kraft J, Yu J, Gao X, Pierce WF, Rahman NA, Fiero MH, Amiri-Kordestani L, de Claro RA, Suzman DL

Citation: Maguire WF, Chang E, Mulkey F, et al. FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. doi:10.1158/1078-0432.CCR-26-1154

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →